Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection Model MML bonhoeffer_rembiszewski_ortiz_nixon_2000_a: View MML bonhoeffer_rembiszewski_ortiz_nixon_2000_b: View MML bonhoeffer_rembiszewski_ortiz_nixon_2000_c: View MML External URL bonhoeffer_rembiszewski_ortiz_nixon_2000 Model types CellML
